NKTR-255, a polymer-conjugated IL-15, enhances CAR T cell therapy by engaging endogenous antitumor immunity
CAR-T cells have yet to show widespread efficacy in solid tumors due in part to poor persistence and dysfunction in the tumor microenvironment. Further, heterogenous expression of target antigens can lead to escape of antigen-null tumors that resist CAR-T killing. Strategies to cooperatively boost both CAR-T and endogenous antitumor immunity may be critical for achieving durable efficacy in cancer patients. NKTR-255 is a polymer-conjugated IL-15 with extended half-life that can boost endogenous T and NK cells, as well as CD19 CAR-T cells in B cell malignancies. However, whether NKTR-255 is sufficient to overcome CAR-T dysfunction in the suppressive solid tumor microenvironment, and how NKTR-255 and CAR-Ts together re-shape endogenous antitumor immunity, is not known. Using mouse models of ROR1+ lung adenocarcinoma, we show that NKTR-255 significantly boosted accumulation and function of tumor-infiltrating CAR-T cells targeting ROR1. Compared with NKTR-255 or CAR-T treatment alone, combination of NKTR-255 and CAR-T therapy increased endogenous tumor-specific T cells that preserved a PD-1+Tcf1+ stem-like phenotype. Consequently, NKTR-255 and CAR-T combination therapy completely eliminated ROR1+ tumor cells and significantly improved survival, with enhanced tumor control dependent on both CAR-Ts and endogenous T cells, though all mice ultimately succumbed to progression of ROR1- tumor. Compared to IL-15-armored CAR-T cells, systemic NKTR-255 induced greater accumulation and reduced terminal differentiation of endogenous tumor-specific T cells, resulting in superior tumor control. Thus, combining NKTR-255 with CAR-T therapy is a promising strategy to enhance both CAR-T and endogenous antitumor immunity to promote coordinated control of aggressive tumors.
Authors
- Megha Sarvothama
- Shivani Srivastava (ORCID: https://orcid.org/0000-0002-1626-8402)
- Mitchell G. Kluesner (ORCID: https://orcid.org/0000-0001-5828-9204)
- Kevin C. Barry (ORCID: https://orcid.org/0000-0003-1064-5964)
- Mark B. Headley (ORCID: https://orcid.org/0000-0002-0924-9326)
- Victor H. Jimenez‐Zepeda (ORCID: https://orcid.org/0000-0002-9294-9437)
- Ekram A. Gad
- Louis Leblanc
- W. Sam Nutt (ORCID: https://orcid.org/0000-0003-4791-4566)
- Eve L. Bingham
- Shannon M. Liudahl (ORCID: https://orcid.org/0000-0002-8587-8204)
- Mario Q. Marcondes
- Sarah M. Garrison (ORCID: https://orcid.org/0000-0002-4246-6621)
- D. M. Miller
- Andrew J. Snyder (ORCID: https://orcid.org/0000-0002-8809-9214)
- Sydney A. Marsh (ORCID: https://orcid.org/0000-0001-8392-1523)
- Madeleine E. Volfbeyn (ORCID: https://orcid.org/0009-0008-9079-9579)
- Madeleine E. Volfbeyn
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- University of California, San Francisco (US)
- University of Washington (US)
- Nektar Therapeutics (United States) (US)
- University of Washington Medical Center (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Cancer Immunology Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1158/2326-6066.cir-25-1569
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.10
Funders
- M.J. Murdock Charitable Trust
- Fred Hutchinson Cancer Research Center
- University of Washington
- National Institutes of Health
- National Cancer Institute